Hummingbird Bioscience extends Series B round
Hummingbird Bioscience, a biotherapeutics company, has extended its Series B funding to $25 million.
Hummingbird Bioscience, a biotherapeutics company, has extended its Series B funding to $25 million.
Copyright PEI Media
Not for publication, email or dissemination